Stereotactic Body Radiation Therapy for Treatment of Primary and Metastatic Pulmonary Malignancies

Surgical Oncology Clinics of North America

Volumn 22, Issue 3, 2013, Pages 463-481

  Kelsey, Chris R ^a   Salama, Joseph K ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Lung cancer; Pulmonary metastases; Stereotactic ablative radiotherapy; Stereotactic body radiation therapy; Surgery

Indexed keywords

SUNITINIB;

BRACHIAL PLEXUS NEUROPATHY; CANCER CONTROL; CANCER STAGING; DISTANT METASTASIS; HUMAN; HYPOXIA; INTERMETHOD COMPARISON; LUNG CANCER; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; METASTASIS RESECTION; PATIENT SAFETY; PRIMARY TUMOR; RADIATION DOSE FRACTIONATION; RADIATION PNEUMONIA; RADIATION RESPONSE; REVIEW; RISK ASSESSMENT; SKIN TOXICITY; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; TREATMENT OUTCOME; WEDGE RESECTION;

HUMANS; LUNG NEOPLASMS; PROGNOSIS; RADIOSURGERY;

EID: 84876879437     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2013.02.011     Document Type: Review

References (93)

1. Potters L., Steinberg M., Rose C., et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004, 60:1026-1032.
2. Palma D., Visser O., Lagerwaard F.J., et al. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010, 28:5153-5159.
3. Wisnivesky J.P., Halm E., Bonomi M., et al. Effectiveness of radiation therapy for elderly patients with unresected stage I and II non-small cell lung cancer. Am J Respir Crit Care Med 2010, 181:264-269.
4. McGarry R.C., Song G., des Rosiers P., et al. Observation-only management of early stage, medically inoperable lung cancer: poor outcome. Chest 2002, 121:1155-1158.
5. Kelsey C.R., Marks L.B., Hollis D., et al. Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. Cancer 2009, 115:5218-5227.
6. Ginsberg R.J., Rubinstein L.V. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995, 60:615-622. [discussion: 622-3].
7. Harpole D.H., Herndon J.E., Young W.G., et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995, 76:787-796.
8. Warren W.H., Faber L.P. Segmentectomy versus lobectomy in patients with stage I pulmonary carcinoma. Five-year survival and patterns of intrathoracic recurrence. J Thorac Cardiovasc Surg 1994, 107:1087-1093. [discussion: 1093-4].
9. Lee J.H., Machtay M., Kaiser L.R., et al. Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy. Radiology 1999, 213:845-852.
10. Martini N., Bains M.S., Burt M.E., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120-129.
11. Dosoretz D.E., Galmarini D., Rubenstein J.H., et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys 1993, 27:507-516.
12. Graham P.H., Gebski V.J., Langlands A.O. Radical radiotherapy for early nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995, 31:261-266.
13. Krol A.D., Aussems P., Noordijk E.M., et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys 1996, 34:297-302.
14. Morita K., Fuwa N., Suzuki Y., et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997, 42:31-36.
15. Sibley G.S., Jamieson T.A., Marks L.B., et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998, 40:149-154.
16. Timmerman R., Papiez L., McGarry R., et al. Extracranial stereotactic radioablation: results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003, 124:1946-1955.
17. Fakiris A.J., McGarry R.C., Yiannoutsos C.T., et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009, 75:677-682.
18. Timmerman R., McGarry R., Yiannoutsos C., et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006, 24:4833-4839.
19. Timmerman R., Paulus R., Galvin J., et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010, 303:1070-1076.
20. Xiao Y., Papiez L., Paulus R., et al. Dosimetric evaluation of heterogeneity corrections for RTOG 0236: stereotactic body radiotherapy of inoperable stage I-II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 73:1235-1242.
21. Olsen J.R., Robinson C.G., El Naqa I., et al. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 81:e299-e303.
22. Onishi H., Shirato H., Nagata Y., et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007, 2:S94-S100.
23. Grutters J.P., Kessels A.G., Pijls-Johannesma M., et al. Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. Radiother Oncol 2010, 95:32-40.
24. Baumann P., Nyman J., Hoyer M., et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009, 27:3290-3296.
25. Bral S., Gevaert T., Linthout N., et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial. Int J Radiat Oncol Biol Phys 2011, 80:1343-1349.
26. Hoyer M., Roed H., Hansen A.T., et al. Prospective study on stereotactic radiotherapy of limited-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 66:S128-S135.
27. Nagata Y., Takayama K., Matsuo Y., et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005, 63:1427-1431.
28. Ricardi U., Filippi A.R., Guarneri A., et al. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung Cancer 2009, 68(1):72-77.
29. Kaskowitz L., Graham M.V., Emami B., et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993, 27:517-523.
30. Sandler H.M., Curran W.J., Turrisi A.T. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1990, 19:9-13.
31. Fang L.C., Komaki R., Allen P., et al. Comparison of outcomes for patients with medically inoperable stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:108-116.
32. Hof H., Herfarth K.K., Munter M., et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003, 56:335-341.
33. Kyas I., Hof H., Debus J., et al. Prediction of radiation-induced changes in the lung after stereotactic body radiation therapy of non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:768-774.
34. Stephans K.L., Djemil T., Reddy C.A., et al. Comprehensive analysis of pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients. J Thorac Oncol 2009, 4:838-844.
35. Overgaard M. Spontaneous radiation-induced rib fractures in breast cancer patients treated with postmastectomy irradiation. A clinical radiobiological analysis of the influence of fraction size and dose-response relationships on late bone damage. Acta Oncol 1988, 27:117-122.
36. Dunlap N.E., Cai J., Biedermann G.B., et al. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:796-801.
37. Pettersson N., Nyman J., Johansson K.A. Radiation-induced rib fractures after hypofractionated stereotactic body radiation therapy of non-small cell lung cancer: a dose- and volume-response analysis. Radiother Oncol 2009, 91:360-368.
38. Voroney J.P., Hope A., Dahele M.R., et al. Chest wall pain and rib fracture after stereotactic radiotherapy for peripheral non-small cell lung cancer. J Thorac Oncol 2009, 4:1035-1037.
39. Welsh J., Thomas J., Shah D., et al. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2011, 81:91-96.
40. Hoppe B.S., Laser B., Kowalski A.V., et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk?. Int J Radiat Oncol Biol Phys 2008, 72:1283-1286.
41. Forquer J.A., Fakiris A.J., Timmerman R.D., et al. Brachial plexopathy from stereotactic body radiotherapy in early-stage NSCLC: dose-limiting toxicity in apical tumor sites. Radiother Oncol 2009, 93:408-413.
42. Grills I.S., Mangona V.S., Welsh R., et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol 2010, 28:928-935.
43. Nagata Y., Hiraoka M., Shibata T., et al. A phase II trial of stereotactic body radiation therapy for operable T1N0M0 non-small cell lung cancer: Japan Clinical Oncology Group (JCOG0403). Proceedings of ASTRO. Int J Radiat Oncol Biol Phys 2010, 78:S27-S28.
44. Okunieff P., Petersen A.L., Philip A., et al. Stereotactic body radiation therapy (SBRT) for lung metastases. Acta Oncol 2006, 45:808-817.
45. Rusthoven K.E., Kavanagh B.D., Burri S.H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 2009, 27:1579-1584.
46. Katz A.W., Carey-Sampson M., Muhs A.G., et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys 2007, 67:793-798.
47. Lee M.T., Kim J.J., Dinniwell R., et al. Phase I study of individualized stereotactic body radiotherapy of liver metastases. J Clin Oncol 2009, 27:1585-1591.
48. Rusthoven K.E., Kavanagh B.D., Cardenes H., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 2009, 27:1572-1578.
49. Chawla S., Chen Y., Katz A.W., et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009, 75(1):71-75.
50. Torok J., Wegner R.E., Burton S.A., et al. Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. Future Oncol 2011, 7:145-151.
51. Salama J.K., Hasselle M.D., Chmura S.J., et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 2012, 118:2962-2970.
52. Chang E.L., Shiu A.S., Mendel E., et al. Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 2007, 7:151-160.
53. Chawla S., Schell M.C., Milano M.T. Stereotactic body radiation for the spine: a review. Am J Clin Oncol 2011, [Epub ahead of print].
54. Kao J., Packer S., Vu H.L., et al. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Cancer 2009, 115:3571-3580.
55. Milano M.T., Katz A.W., Zhang H., et al. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 2012, 83:878-886.
56. Wulf J., Baier K., Mueller G., et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005, 77:83-87.
57. Blomgren H., Lax I., Naslund I., et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol 1995, 34:861-870.
58. Nagata Y., Negoro Y., Aoki T., et al. Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2002, 52:1041-1046.
59. Whyte R.I., Crownover R., Murphy M.J., et al. Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 2003, 75:1097-1101.
60. Le Q.T., Loo B.W., Ho A., et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol 2006, 1:802-809.
61. Lee S.W., Choi E.K., Park H.J., et al. Stereotactic body frame based fractionated radiosurgery on consecutive days for primary or metastatic tumors in the lung. Lung Cancer 2003, 40:309-315.
62. Goodman K.A., Wiegner E.A., Maturen K.E., et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 2010, 78:486-493.
63. Hellman S., Weichselbaum R.R. Oligometastases. J Clin Oncol 1995, 13:8-10.
64. Weichselbaum R.R., Hellman S. Oligometastases revisited. Nat Rev Clin Oncol 2011, 8(6):378-382.
65. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg 1997, 113:37-49.
66. Fong Y., Cohen A.M., Fortner J.G., et al. Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938-946.
67. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
68. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
69. Miller G., Biernacki P., Kemeny N.E., et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J Am Coll Surg 2007, 205:231-238.
70. Bezjak A. Palliative therapy for lung cancer. Semin Surg Oncol 2003, 21:138-147.
71. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
72. Hasselle M.D., Haraf D.J., Rusthoven K.E., et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 2012, 7:376-381.
73. Lussier Y.A., Xing H.R., Salama J.K., et al. MicroRNA expression characterizes oligometastasis(es). PLoS One 2011, 6:e28650.
74. Hof H., Hoess A., Oetzel D., et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol 2007, 183:673-678.
75. Wulf J., Haedinger U., Oppitz U., et al. Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 2004, 60:186-196.
76. McCammon R., Schefter T.E., Gaspar L.E., et al. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2009, 73:112-118.
77. Corbin K, Ranck M, Hasselle M, et al. Feasibility and toxicity of hypofractionated image-guided radiotherapy for large volume limited metastatic disease. Pract Radiat Oncol 2012, in press.
78. Rodriguez-Ruiz M.E., San Miguel I., Gil-Bazo I., et al. Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review. Radiat Oncol 2012, 7:50.
79. Siva S., MacManus M., Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol 2010, 5:1091-1099.
80. Yenice K.M., Partouche J., Cunliffe A., et al. Analysis of radiation pneumonitis (RP) incidence in a phase I stereotactic body radiotherapy (SBRT) dose escalation study for multiple metastases. Int J Radiat Oncol Biol Phys 2010, 78:S25. [abstract 53].
81. Guckenberger M., Baier K., Polat B., et al. Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 2010, 97:65-70.
82. Zhang Y., Xiao J.P., Zhang H.Z., et al. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J 2011, 124:4132-4137.
83. Ricardi U., Filippi A.R., Guarneri A., et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer 2012, 75:77-81.
84. Dhakal S., Corbin K.S., Milano M.T., et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys 2012, 82:940-945.
85. Ranck M., Golden D., Corbin K., et al. Stereotactic body radiotherapy for the treatment of oligometastatic renal cell carcinoma. Am J Clin Oncol 2012, [Epub ahead of print].
86. Stinauer M.A., Kavanagh B.D., Schefter T.E., et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol 2011, 6:34.
87. Takeda A., Kunieda E., Ohashi T., et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol 2011, 101:255-259.
88. Peulen H., Karlsson K., Lindberg K., et al. Toxicity after reirradiation of pulmonary tumours with stereotactic body radiotherapy. Radiother Oncol 2011, 101:260-266.
89. Milano M.T., Philip A., Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 2009, 73:832-837.
90. Hamamoto Y., Kataoka M., Yamashita M., et al. Local control of metastatic lung tumors treated with SBRT of 48 Gy in four fractions: in comparison with primary lung cancer. Jpn J Clin Oncol 2010, 40:125-129.
91. Uematsu M., Shioda A., Tahara K., et al. Focal, high dose, and fractionated modified stereotactic radiation therapy for lung carcinoma patients: a preliminary experience. Cancer 1998, 82:1062-1070.
92. Yoon S.M., Choi E.K., Lee S.W., et al. Clinical results of stereotactic body frame based fractionated radiation therapy for primary or metastatic thoracic tumors. Acta Oncol 2006, 45:1108-1114.
93. Norihisa Y., Nagata Y., Takayama K., et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys 2008, 72:398-403.